Genmab — April 2024
-
Genmab og partner henter fuld amerikansk godkendelse til livmoderhalskræftmiddel https://www.proinvestor.com/investornyt/1152227/genmab-og-partner-henter-fuld-amerikansk-godkendelse-til-livmoderhalskraeftmiddel
-
This full approval is the minimum requirement to continue with Tivdak and therefore an important step. It will depend on how much new owner Pfizer sees in the drug, but the EMA application and current conversations with regulators to continue also in head and neck cancer bode well for now.
-
Tivdak seems to go a little bit under the radar, but 'According to GlobalData’s patient-based forecast, Tivdak is forecast to generate sales of $1.4bn in the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada) by 2030'
-
Highlights from ESMO 2023: Antibody-drug conjugates and bispecific T-cell engagers
At ESMO 2023, much of the focus was on new data for antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs)
Clinical Trials Arena (www.clinicaltrialsarena.com)
-
Thanks E L 09:48. Can you also see what’s the forecast for epcoritamab is by 2030?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind